Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 May 29;20(1):485.
doi: 10.1186/s12885-020-06968-1.

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)

Antoine Brouquet  1   2 , Jean-Baptiste Bachet  3 , Florence Huguet  4 , Mehdi Karoui  5 , Pascal Artru  6 , Charles Sabbagh  7 , Jérémie H Lefèvre  8 , Dewi Vernerey  9 , Christophe Mariette  10 , Eric Vicaut  11 , Stephane Benoist  12   13 ; on behalf the FRENCH , GRECCAR, PRODIGE study groups
Affiliations
Comparative Study

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)

Antoine Brouquet et al. BMC Cancer. .

Abstract

Background: Preoperative radiochemotherapy (RCT) is recommended in France prior to total mesorectal excision in patients with mid or low locally advanced rectal cancer (LARC) (cT3/T4 and/or N+) because it has been shown to improve local control. Preoperative RCT has also disadvantages including the absence of proven impact on metastatic recurrence and the risk of late side effects on bowel and genitourinary function. In patients with primarily resectable LARC, preoperative systemic chemotherapy without pelvic irradiation could be used as an alternative to RCT.

Methods: This study is a multicenter, open-label randomized, 2-arm phase III non-inferiority trial. Patients with mid or low resectable LARC (cT3N0 or cT1-T3N+ with circumferential resection margin [CRM] > 2 mm on pretreatment MRI) will be randomized to either modified FOLFIRINOX for 3 months or RCT (Cap50 intensified-modulated radiotherapy). All patients have restaging MRI after preoperative treatment. The primary endpoint is 3-year progression-free survival (PFS) from the time to randomization including progression during preoperative treatment. Secondary endpoints are treatment related toxicity, treatment compliance, R0 resection rate, sphincter saving surgery rate, postoperative morbidity and mortality rates, loco-regional recurrence free survival, overall survival, bowel and sexual functions at diagnosis, quality of life, radiologic and pathologic response after preoperative treatment. The number of patients required is 574.

Discussion: The choice of modified FOLFIRINOX for preoperative chemotherapy is supported by recent and consistent data on safety and efficacy of this regimen on rectal cancer. The use of preoperative chemotherapy instead of RCT could be associated with pronounced advantages in terms of functional results and quality of life in cancer survivors. However and first of all, the non-inferiority of preoperative chemotherapy compared to RCT on oncologic outcome has to be validated. If this study demonstrates the non-inferiority of chemotherapy compared to RCT, this can lead to a crucial change in clinical practice in a large subset of rectal cancer patients.

Trial registration: ClinicalTrials.gov NCT03875781 (March 15, 2019). Version 1.1.

Keywords: Circumferential resection margin; Functional result; Locally advanced rectal cancer; Preoperative chemotherapy; Preoperative radiochemotherapy; Quality of life.

PubMed Disclaimer

Conflict of interest statement

AB:

Speaker fee: Takeda, Merck-Serono, Abbvie, Roche, Amgen, Janssen-Cilag.

Invitation to scientific meeting: Biom’up, Roche, Win’up surgical system, Intuitive surgical.

JBB:

Employment, (Merck Serono), honoraria (Amgen, Bayer, Celgene,Merck Serono, Roche, Sanofi/Aventis, Servier/Pfizer), consulting or advisory role (Amgen, Bayer, Merck Serono, Servier/Pfizer), non-financial disclosure (Amgen, Merck, Serono, Roche);

EV: None.

MK: None.

PA:

honoraria (Roche, Amgen, Bayer, Servier, Lilly, Merck Serono), consulting or advisory role (Roche, Merck Serono, Servier), non-financial disclosure (Roche, Merck Serono, Bayer).

CS: None.

JHL:

Honoraria from Vifor Pharma (2012), Takeda (2018), and MDStart (2018) and being invited to an international medical congress by Sanofi (2015), Eumedica (2015), Biomup (2019).

Consultency for Safeheal.

DW: None.

CM: None.

FH: None.

SB:

Speaker fee: Merck Serono, Roche, Amgen, Nestlé, Takeda, Abbvie, Biom’up, Sanofi, Servier, Win’up.

Scientific board/Consultency: Amgen, Biom’up, Win’up.

Figures

Fig. 1
Fig. 1
study design
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1:1479–1482. doi: 10.1016/S0140-6736(86)91510-2. - DOI - PubMed
    1. Bosset J-F, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–1123. doi: 10.1056/NEJMoa060829. - DOI - PubMed
    1. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–646. doi: 10.1056/NEJMoa010580. - DOI - PubMed
    1. Gérard J-P, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin M-T, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–4625. doi: 10.1200/JCO.2006.06.7629. - DOI - PubMed
    1. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:979–989. doi: 10.1016/S1470-2045(15)00159-X. - DOI - PubMed

Publication types

MeSH terms

Associated data